* Read the article on page 3.
* Take the test, recording your answers in the test answers section (Section B) of the CE enrollment form. Each question has only one correct answer.
* Complete registration information (Section A) and course evaluation (Section C).
* Mail completed test with registration fee to: Lippincott Williams & Wilkins, CE Group, 2710 Yorktowne Blvd., Brick, NJ 08723.
* Within 4-6 weeks after your CE enrollment form is received, you will be notified of your test results.
* If you pass, you will receive a certificate of earned contact hours and answer key. If you fail, you have the option of taking the test again at no additional cost.
* A passing score for this test is 12 correct answers.
* Need CE STAT? Visit www.nursingcenter.com for immediate results, other CE activities and your personalized CE planner tool.
* No Internet access? Call 1-800-787-8985, for other rush service options.
* Questions? Contact Lippincott Williams & Wilkins: 1-800-787-8985.
Registration Deadline: February 28, 2013
The authors have disclosed that they have no significant relationship with or financial interest in any commercial companies that pertain to this educational activity.
Lippincott Williams & Wilkins, publisher of Journal of Neuroscience Nursing, will award 2.5 contact hours for this continuing nursing education activity.
Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 2.5 contact hours. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #FBN2454. Your certificate is valid in all states.
The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers only to its continuing nursing education activities and does not imply Commission on Accreditation approval or endorsement of any commercial product.
Payment and Discounts:
* The registration fee for AANN members is $18.75; for nonmembers, $37.50.
* AANN members-to get the discounted price (50% off) when taking the test online, log into the secure "Members Only" area of www.aann.org to get the discount code. Use the code when paying for CE courses on www.nursingcenter.com/CE/JNN.
* Send two or more tests in any nursing journal published by LWW together by mail, and deduct $0.95 from the price of each test.
* We offer special discounts for as few as six tests and institutional bulk discounts for multiple tests. Call 1-800-787-8985 for more information.
CE TEST QUESTIONS
GENERAL PURPOSE STATEMENT: To provide the registered professional nurse with information about emerging oral therapies for multiple sclerosis (MS).
LEARNING OBJECTIVES: After reading this article and taking this test, the reader will be able to:
1. Describe MS characteristics and traditional therapy.
2. Describe drug administration and efficacy.
3. Identify side effects and related patient education.
1. Traditional therapy for MS included medications to treat
a. heart failure.
2. Historically, the route of administration for MS treatment has been
3. Which of the new oral therapies for MS was first to be approved?
4. MS is characterized by
a. increased granulocytes.
b. decreased monocytes.
c. increased lymphocytes.
d. decreased erythrocytes.
5. MS is mainly characterized by destruction of
b. mononuclear cells.
6. Which cells can make antibodies to myelin?
b. T cells
c. B cells
d. mononuclear cells
7. Which statement about cladribine therapy is true?
a. It is indicated for progressive MS.
b. It is administered once a day.
c. It demonstrates no significant change in relapse time.
d. It kills lymphocytes by damaging RNA.
8. Cited side effects of cladribine include
a. liver failure.
b. back pain.
d herpes zoster.
9. Cladribine is administered
a. for a short course followed by long periods without dosing.
b. for 4-5 weeks followed by a 2-week hiatus.
c. daily, with no interruption in dosing.
d. initially at high doses, with gradual tapering.
10. Treatment with fingolimod
a. demonstrates no change in annualized relapse rate.
b. treats both progressive and relapsing MS.
c. demonstrates reduced disability via a valid disability scale.
d. causes lymphocyte death.
11. Frequent fingolimod side effects include
c. Budd-Chiari syndrome.
d. fetal abnormalities.
12. Because of possible adverse effects, patients taking fingolimod should routinely see a(an)
c. vascular surgeon.
13. Forced vital capacity in patients on fingolimod was
c. slightly decreased.
d. significantly decreased.
14. One frequent side effect of fingolimod is
b. elevated creatinine.
15. Patients on fingolimod are most likely to have a problem with
a. central vision.
b. peripheral vision.
c. retinal detachment.
d. corneal erosion.
16. Compared with placebo, treatment with laquinimod demonstrated
a. lower relapse rate.
b. slower disability progression.
c. transient increases in creatinine.
d. complaints of back pain.
17. Patients taking terifunomide demonstrated
a. worse disability scores.
b. reduced median number of active lesions.
c. higher relapse rate.
d. higher need for steroid use.
18. Patients taking BG-12 should be educated that the side effect of flushing usually
a. prompts discontinuation of the medication.
b. starts within 10 minutes of administration.
c. diminishes in 1-2 months.
d. lasts for 6 hours.